- Login
- Register & Subscribe
- Langue: EN FR DE
Research & University News
Sygnis says Phase 2 stroke trial fails
Friday 16 December 2011
In another set-back for developers of potential stroke treatments, Sygnis Pharma AG said its Phase 2 study of a growth factor for acute ischaemic stroke failed to meet its primary and secondary endpoints. The product is a recombinant version of granulocyte colony-stimulating factor (G-CSF).
Location
Germany
Neovacs completes enrolment for immunotherapy trial
Thursday 15 December 2011
Neovacs SA of France has completed the recruitment of patients for the first phase of a multicentre Phase 2 trial of its immunotherapy for Crohn’s disease. The primary objective will be to evaluate the ability of the therapy to induce clinical remission.
Location
France
Ablynx in Phase 1 study of therapy for RSV
Tuesday 13 December 2011
Ablynx NV has started a Phase 1 study in healthy volunteers of an antibody-derived therapeutic protein for the treatment of respiratory syncytial viral infections. To date, there is only one approved antibody therapeutic for this disease.
Location
Belgium
Gene therapy shows benefit in patients with haemophilia B
Sunday 11 December 2011
Researchers from University College London and colleagues have reported the successful administration of a gene therapy to patients with haemophilia B. The study appears in the 10 December New England Journal of Medicine.
Location
United Kingdom
Transplantation of bioartificial trachea reported
Friday 9 December 2011
A team of European researchers has reported the successful transplantation of a synthetic trachea into a patient with tracheal cancer using a scaffold which was seeded with the patient’s own stem cells.
Location
Sweden
EMBL raises €40 million for early life science
Wednesday 7 December 2011
Early-stage life science projects received another boost on Wednesday with the launch of a new technology fund by the venture capital arm of the European Molecular Biology Laboratory (EMBL). The new fund, EMBL Technology Fund II, has raised €40 million in a first closing.
Location
Germany
Zealand Pharma reports on lixisenatide trial
Wednesday 7 December 2011
Zealand Pharma A/S said that the latest clinical data for its prospective type 2 diabetes treatment, lixisenatide (Lyxumia) in combination with long-acting insulin, showed a significant reduction in plasma glucose concentrations (HbA1c).
Location
Denmark
AstraZeneca to donate compounds to UK academia
Monday 5 December 2011
AstraZeneca Plc has announced plans to make 22 compounds available to medical researchers in the UK free of charge in a bid to promote more drug discovery. The compounds are not the focus of current research at the company.
Location
United Kingdom
Addex reports on signalling pathways implicated in diabetes
Sunday 4 December 2011
Scientists working for Addex Pharmaceuticals Ltd of Switzerland have reported discovering an apparently novel interaction between two members of the G-protein coupled receptor (GPCR) family which may have implications for the treatment of diabetes.
Location
Switzerland
Galapagos reports data on JAK inhibitor
Tuesday 22 November 2011
Galapagos NV has become the latest company to report positive clinical data for an oral Janus kinase (JAK) inhibitor in rheumatoid arthritis, an autoimmune disease that is estimated to affect about 1% of the world’s population. Current treatments include non-steroidal anti-inflammatory drugs; methotrexate, and biologic medicines.
Location
Belgium
Select a News Category
Recent Appointments
Pascale Witz to head strategic development at Sanofi
Monday May 6 2013
Srinivas Akkaraju joins Sofinnova Ventures
Monday May 6 2013
Vicente Anido nominated to Nicox board
Monday May 6 2013
Jeremy Farrar named director of the Wellcome Trust
Monday May 6 2013
Harry Kirsch becomes CFO at Novartis
Monday May 6 2013